Alterations of the endocannabinoid system in an animal model of migraine: Evaluation in cerebral areas of rat

Cephalalgia ◽  
2009 ◽  
Vol 30 (3) ◽  
pp. 296-302 ◽  
Author(s):  
R Greco ◽  
V Gasperi ◽  
G Sandrini ◽  
G Bagetta ◽  
G Nappi ◽  
...  

Endocannabinoids are involved in the modulation of pain and hyperalgesia. In this study we investigated the role of the endocannabinoid system in the migraine model based on nitroglycerin-induced hyperalgesia in the rat. Male rats were injected with nitroglycerin (10 mg/kg, i.p.) or vehicle and sacrificed 4 h later. The medulla, the mesencephalon and the hypothalamus were dissected out and utilized for the evaluation of activity of fatty acid amide hydrolase (that degrades the endocannabinoid anandamide), monoacylglycerol lipase (that degrades the endocannabinoid 2-arachidonoylglycerol), and binding sites specific for cannabinoid (CB) receptors. The findings obtained show that nitroglycerin-induced hyperalgesia is associated with increased activity of both hydrolases and increased density of CB binding sites in the mesencephalon. In the hypothalamus we observed an increase in the activity of fatty acid amide hydrolase associated with an increase in density of CB binding sites, while in the medulla only the activity of fatty acid amide hydrolase was increased. Anandamide also proved effective in preventing nitroglycerin-induced activation (c-Fos) of neurons in the nucleus trigeminalis caudalis. These data strongly support the involvement of the endocannabinoid system in the modulation of nitroglycerin-induced hyperalgesia, and, possibly, in the pathophysiological mechanisms of migraine.

2021 ◽  
Vol 22 (3) ◽  
pp. 1047
Author(s):  
Dorsa Rafiei ◽  
Nathan J. Kolla

Altered activity of fatty acid amide hydrolase (FAAH), an enzyme of the endocannabinoid system, has been implicated in several neuropsychiatric disorders, including major depressive disorder (MDD). It is speculated that increased brain FAAH expression is correlated with increased depressive symptoms. The aim of this scoping review was to establish the role of FAAH expression in animal models of depression to determine the translational potential of targeting FAAH in clinical studies. A literature search employing multiple databases was performed; all original articles that assessed FAAH expression in animal models of depression were considered. Of the 216 articles that were screened for eligibility, 24 articles met inclusion criteria and were included in this review. Three key findings emerged: (1) FAAH expression is significantly increased in depressive-like phenotypes; (2) genetic knockout or pharmacological inhibition of FAAH effectively reduces depressive-like behavior, with a dose-dependent effect; and (3) differences in FAAH expression in depressive-like phenotypes were largely localized to animal prefrontal cortex, hippocampus and striatum. We conclude, based on the animal literature, that a positive relationship can be established between brain FAAH level and expression of depressive symptoms. In summary, we suggest that FAAH is a tractable target for developing novel pharmacotherapies for MDD.


2019 ◽  
Vol 33 (S1) ◽  
Author(s):  
Ashfaq Ahmad ◽  
Sara K. Dempsey ◽  
Zdravka Daneva ◽  
Ningjun Li ◽  
Pin‐Lan Li ◽  
...  

2017 ◽  
Vol 174 (21) ◽  
pp. 3837-3847 ◽  
Author(s):  
Erin M Rock ◽  
Guillermo Moreno-Sanz ◽  
Cheryl L Limebeer ◽  
Gavin N Petrie ◽  
Roberto Angelini ◽  
...  

2014 ◽  
Vol 24 (9) ◽  
pp. 1511-1523 ◽  
Author(s):  
Gaurav Bedse ◽  
Roberto Colangeli ◽  
Angelo M. Lavecchia ◽  
Adele Romano ◽  
Fabio Altieri ◽  
...  

2020 ◽  
Vol 85 ◽  
pp. 106615
Author(s):  
Harisa Ferizovic ◽  
Natasa Spasojevic ◽  
Bojana Stefanovic ◽  
Milica Jankovic ◽  
Sladjana Dronjak

2006 ◽  
Vol 49 (15) ◽  
pp. 4650-4656 ◽  
Author(s):  
Susanna M. Saario ◽  
Antti Poso ◽  
Risto O. Juvonen ◽  
Tomi Järvinen ◽  
Outi M. H. Salo-Ahen

2012 ◽  
Vol 9 (4) ◽  
pp. 801-813 ◽  
Author(s):  
Vinogran Naidoo ◽  
David A. Karanian ◽  
Subramanian K. Vadivel ◽  
Johnathan R. Locklear ◽  
JodiAnne T. Wood ◽  
...  

2019 ◽  
Vol 4 (1) ◽  
pp. 42-50 ◽  
Author(s):  
Annalaura Sabatucci ◽  
Monica Simonetti ◽  
Daniel Tortolani ◽  
Clotilde B. Angelucci ◽  
Enrico Dainese ◽  
...  

2021 ◽  
Author(s):  
Alex Mabou Tagne

The endocannabinoid system (ECS) modulates a variety of physiological processes, attracting considerable attention as a potential target for therapeutic intervention. This complex system is activated by the lipid-derived mediators anandamide and 2-arachidonoyl-sn-glycerol (2-AG), which mainly engage the cannabinoid receptor subtypes 1 (CB1) and 2 (CB2). The biological actions of anandamide and 2-AG are terminated by internalization and intracellular enzymatic hydrolysis catalyzed primarily by the serine hydrolases fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL), respectively. Here, we provide an overview of ECS and discuss the implications for advancing pharmacological tools that interfere with such a system as next-generation therapeutics. This review contains 4 figures, 3 tables and 41 references Keywords: Endocannabinoid; anandamide; 2-Arachidonoyl-sn-glycerol; fatty acid amide hydrolase; monoacylglycerol lipase; cannabinoid receptors; N-acylethanolamine acid amidase; Δ9-tetrahydrocannabinol.


Sign in / Sign up

Export Citation Format

Share Document